Background Adalimumab (ADA) is an effective medication in the treatment of rheumatoid
arthritis (RA). However, it is not clear whether the use of ADA is associated with altered use …

Background Immunogenicity with therapeutic proteins has been linked to reduction in both
efficacy and safety in patients (pts) with RA. 1, 2 We previously reported in clinical trials that …

Background Many patients with rheumatoid arthritis (RA) are successfully treated with
tumour necrosis factor inhibitors (TNFi). We recently developed a novel assay that can …

Background Clinical trial data support the superiority of combining adalimumab (ADA) with
DMARD (s) vs ADA alone. The use and effectiveness of ADA+ DMARD (s) over …

Background In a study on continuation of adalimumab (ADA) therapy in Japan, the
concomitant use of MTX with ADA was associated with higher efficacy and treatment …

Objectives To study infection rates in patients with low immunoglobulin (Ig) serum
concentrations following administration of rituximab (RTX) in RA clinical trials. Methods …

Background: Infliximab is still a widely used biologic agent in treatment of rheumatoid
arthritis (RA). Because infliximab is expensive and can have adverse events, identification of …

Background In the Phase III, double-blind, placebo (PBO)-controlled AIM study, abatacept
(ABA)+ MTX significantly inhibited structural damage progression vs PBO+ MTX in pts with …

Background Duration of disease has a considerable impact on the response to treatment
with DMARDs in patients (pts) with RA. Those with longer disease duration do not respond …

Background Studies combining immunosuppressive biologics have shown an increased risk
of infections. Objectives Examine the occurrence of serious and opportunistic infections in …